Puberty blockers banned after Cass Review because effects unknown
Tom Swarbrick said:
“These trials are needed, scientists say, because not enough is understood about effects of puberty blockers on children. That is why, after the Cass Review, the prescription of them to children in The UK was banned.”
Framing the ban as a direct, logical consequence of the Cass Review and scientific uncertainty makes it sound like a straightforward evidence-based decision. Listeners who trust regulatory bodies will assume the ban reflects a clear scientific consensus that the treatment is unsafe.
The Cass Review did not find that puberty blockers are harmful: it called for more structured research into a treatment that had already been in clinical use for decades, including in children experiencing early puberty for reasons unrelated to gender. That is a meaningful distinction, because the NHS England ban was a policy decision made in a particular political moment, not a finding that the treatment causes damage. Clinical trials were commissioned to gather better evidence, which is a normal part of medicine, not evidence that something has been shown to be unsafe. Young people who hear that puberty blockers were banned because they are proven dangerous are being given a version of events that the Cass Review itself does not support, and that misunderstanding has real consequences for families trying to make sense of their options.
Young people and their families who hear this and conclude that puberty blockers were banned because they are proven to be harmful, when the evidence picture is more complex.